An observational study in Venous Thromboembolism (VTE), Acute Myocardial Infarction With ST Segment Elevation and Stroke (in Patients With Atrial Fibrillation), sponsored by University of Aarhus. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-21.
Sponsored by University of Aarhus · Observational
The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial infarction (AMI) or ischaemic stroke compared to healthy volunteers. The main questions it aims to answer are:
Participants with VTE, AMI or stroke will be giving a blood sample at diagnosis and again after 3 and 12 months of follow-up. Healthy volunteers will be giving a blood sample once.
694 studies on the registry are indexed under Venous Thromboembolism; 152 are open to participants now.
This study's planned enrollment of 340 is below the median of 700 across 283 observational studies indexed under Venous Thromboembolism.
Browse Venous Thromboembolism studies →University of Aarhus is the lead sponsor of 1,274 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants will be recruited at Aarhus University Hospital at the department of Cardiology (AMI, VTE), Neurology (Stroke) and Radiology (VTE) and at the Blood Bank (Healthy volunteers).
VTE group:
AMI group:
Stroke group:
Healthy group:
- Healthy
Exclusion Criteria:
VTE - Pulmonary embolism incidentally detected by CTA conducted for purposes unrelated to pulmonary embolism assessment without concomitant DVT
AMI
Stroke
- Stroke from other causes, e.g. findings pointing towards large vessel disease
Healthy
Patients with acute deep vein thrombosis diagnosed on UL or pulmonary embolism diagnosed on CTA. \>18 years of age. 120 patients in total.
With ST segment elevation on ECG and confirmed culprit lesion on coronary angiography. \>18 years of age. 50 patients in total.
Stroke confirmed on MRI and diagnosis of atrial fibrillation. \>18 years of age. 50 patients in total.
No known or prior diseases, no medication. \>18 years of age. 120 in total.
Platelet levels of heat shock protein 47 (HSP47) in patients with thrombosis compared to healthy controls
The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry.
Time frame: From enrollment to end of follow-up at 12 months after enrollment. At 3 time points.
Changes in platelet levels of HSP47 over time in patients with thrombosis
The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry.
Time frame: From enrollment to 12 months of follow-up. Measured at 3 time points.
Platelet levels of HSP47 in association to platelet function
The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry. Platelet function will be assessed by platelet aggregation and activation using impedance aggregometry and flow cytometry.
Time frame: From enrollment to 12 months of follow-up. Measured at 3 time points.
Platelet levels of HSP47 in association to fibrinolytic capacity
The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry. Fibrinolytic capacity will be assessed by ROTEM (R) tPA methods established in our lab, and by plasma fibrinolysis analyses.
Time frame: From enrollment to 12 months of follow-up. Measured at 3 time points.
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Aarhus